Genetic and clinical markers of elevated liver fat content in overweight and obese hispanic children

Obesity

Volumn 21, Issue 12, 2013, Pages

  Walker, Ryan W ^a   Sinatra, Frank ^a   Hartiala, Jaana ^a   Weigensberg, Marc ^a   Spruijt Metz, Donna ^a   Alderete, Tanya L ^a   Goran, Michael I ^a   Allayee, Hooman ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3;

ADOLESCENT; ALLELE; APOC3 GENE; ARTICLE; CHILD; CHILDHOOD OBESITY; CONTROLLED STUDY; FAT CONTENT; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PNPLA3 GENE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ALANINE TRANSAMINASE; ALLELES; ANTHROPOMETRY; APOLIPOPROTEIN C-III; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; CHILD; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GENOTYPE; HISPANIC AMERICANS; HUMANS; LIPASE; MALE; MEMBRANE PROTEINS; OBESITY; OVERWEIGHT; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TRIGLYCERIDES;

EID: 84889688409     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20523     Document Type: Article

References (40)

1. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE,. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 13-24.
2. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE,. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006; 43: 413-427.
3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. Gastroenterology 2012; 142: 1592-1609.
4. Lavine JE, Schwimmer JB,. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004; 8: 549-558.
5. Goran MI, Walker R, Le KA, Mahurkar S, Vikman S, Davis JN, et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010; 59: 3127-3130.
6. Prati D, Colli A, Conte D, Colombo M,. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42: 650-656.
7. Reid AE,. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-723.
8. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
9. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
10. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010; 362: 1082-1089.
11. Hasson RE, Adam TC, Davis JN, Weigensberg MJ, Ventura EE, Lane CJ, et al. Ethnic differences in insulin action in obese African-American and Latino adolescents. J Clin Endocrinol Metab 2010; 95: 4048-4051.
12. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: 462-468.
13. Henry RJ, Chiamori N, Golub OJ, Berkman S,. Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. Am J Clin Pathol 1960; 34: 381-398.
14. Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138: 1357-1364.
15. Sackett DL, Richardson WS, Rosenberg W, Haynes RB,. Evidence-based Medicine: How to Practice and Teach EBM, 2nd ed. New York: Churchill Livingstone, 2000
16. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC,. Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47: 1363-1370.
17. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
18. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I,. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983-983.
19. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE,. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005; 115: 561-565.
20. Ruhl, CE, Everhart JE,. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012; 55: 447-454.
21. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52: 1056-1060.
22. Romeo S, Sentinelli F, Cambuli VM, Incani M, Congiu T, Matta V, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010; 53: 335-338.
23. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ,;, NASH CRN,. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
24. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ,. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-2116.
25. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52: 1274-1280.
26. Yang Z, Wen J, Tao X, Lu B, Du Y, Wang M, et al. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep 2011; 38: 1145-1150.
27. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2011; 55: 781-789.
28. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992; 90: 1889-1900.
29. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL,. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249: 790-793.
30. Hyysalo J, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, et al. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2012; 27: 951-956.
31. Lee HY, Birkenfeld AL, Jornayvaz FR, Jurczak MJ, Kanda S, Popov V, et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011; 54: 1650-1660.
32. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH,. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011; 53: 467-474.
33. Sentinelli F, Romeo S, Maglio C, Incani M, Burza MA, Scano F, et al. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis 2011; 10: 93-93.
34. Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 2011; 55: 1409-1414.
35. Duseja A, Aggarwai R,. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. J Gastroenterol Hepatol 2012; 27: 848-851.
36. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP,. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269.
37. Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011; 21: 431-439.
38. Sartorio A, Del Col A, Agosti F, Mazzilli G, Bellentani S, Tiribelli C, et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007; 61: 877-883.
39. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S,. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
40. Maffeis C, Banzato C, Rigotti F, Nobili V, Valandro S, Manfredi R, et al. Biochemical parameters and anthropometry predict NAFLD in obese children. JPGN 2011; 53: 590-593.